Dr David Baker

Dr David Baker earned his PhD from The University of Sheffield in 2015 for investigating the role of astrocytes in SOD1-related amyotrophic lateral sclerosis (ALS). Following a short post-doctoral spell, David joined the Cellular Assay Development team in AstraZeneca, initially supporting Neuroscience and Oncology projects but with an ever-growing interest complex models and assays for Immuno-Oncology . In 2020 David secured a position specialising in assay development for cellular therapies and is working on wide-ranging projects encompassing whole genome pooled and arrayed CRISPR screens through to bespoke co-culture models.